Researchers at the University of Illinois at Chicago have found that genetic differences might predict the patient’s response to ADD medication, namely stimulant medication. A study found that children with a variant form of a dopamine transporter gene — a variant known to be associated with ADHD — responded poorly to one of the most […]
ADD Medication Response May Be Conditioned By Your Genes Read More »
Found an online press release for a teleconference with Marc Berthiaume, Director of the Marketed Pharmaceuticals Division of the Marketed Health Products Directorate of Health Canada on Adderall XR which has recently been put back on the market after suspending it in February 2005, in a controversial move. I.e., it was supposedly pulled of the
Health Canada has allowed Shire BioChem, the makers of Adderall XR to resume sales of Adderall XR. Health Canada appointed an external and independent committee, the New Drug Committee (NDC), which concluded that Health Canada’s original actions in banning the drug were appropriate and that the drug should be reintroduced to the Canadian market once
Health Canada allows Adderall XR® Back on the Canadian Market Read More »
Florida State University Economics Professor Farasat Bokhari co-authored a study published in the journal Pharmacoepidemiology and Drug Safety that found wide variations in the distribution of stimulant medication to treat ADHD. The researchers found that the counties where ADHD drug use was the highest had higher per capita income, lower unemployment rates, greater population density
Update: check out Part One and Part Three of the Crystal Meth Series of posts More on the missing (in the public media at least) ADD connection with crystal meth. The Journal of Addictive Diseases has an article called “Cognitive deficits among methamphetamine users with ADHD symptomatology.” The preliminary data suggests that executive function deficits